124 related articles for article (PubMed ID: 36184755)
1. Brief Report: Dapivirine Ring HIV-1 Prevention Effectiveness for Women Engaged in Vaginal and Anal Intercourse: Insights From Mathematical Modeling.
Peebles K; Brown ER; Hendrix CW; Palanee-Phillips T; van der Straten A; Harkoo I; Reddy K; Mirembe BG; Jeenarain N; Hillier SL; Baeten JM; Barnabas RV;
J Acquir Immune Defic Syndr; 2023 Feb; 92(2):122-126. PubMed ID: 36184755
[TBL] [Abstract][Full Text] [Related]
2. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.
Stalter RM; Dong TQ; Hendrix CW; Palanee-Phillips T; van der Straten A; Hillier SL; Kiweewa FM; Mgodi NM; Marzinke MA; Bekker LG; Soto-Torres L; Baeten JM; Brown ER;
J Infect Dis; 2024 Apr; 229(4):1158-1165. PubMed ID: 38099506
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Anal Intercourse, HIV-1 Risk, and Efficacy in a Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention.
Peebles K; van der Straten A; Palanee-Phillips T; Reddy K; Hillier SL; Hendrix CW; Harkoo I; Gati Mirembe B; Jeenarain N; Baeten JM; Brown ER;
J Acquir Immune Defic Syndr; 2020 Mar; 83(3):197-201. PubMed ID: 31809308
[TBL] [Abstract][Full Text] [Related]
4. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
[TBL] [Abstract][Full Text] [Related]
5. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
[TBL] [Abstract][Full Text] [Related]
6. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
7. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
Reddy K; Kelly C; Brown ER; Jeenarain N; Naidoo L; Siva S; Bekker LG; Nair G; Makanani B; Chinula L; Mgodi N; Chirenje Z; Kiweewa FM; Marrazzo J; Bunge K; Soto-Torres L; Piper J; Baeten JM; Palanee-Phillips T;
AIDS; 2020 Mar; 34(4):559-567. PubMed ID: 31764068
[TBL] [Abstract][Full Text] [Related]
8. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
[TBL] [Abstract][Full Text] [Related]
10. Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.
Laborde ND; Pleasants E; Reddy K; Atujuna M; Nakyanzi T; Chitukuta M; Naidoo S; Palanee-Phillips T; Baeten JM; Montgomery ET;
AIDS Behav; 2018 Feb; 22(2):437-446. PubMed ID: 29151197
[TBL] [Abstract][Full Text] [Related]
11. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial.
Mayo AJ; Browne EN; Montgomery ET; Torjesen K; Palanee-Phillips T; Jeenarain N; Seyama L; Woeber K; Harkoo I; Reddy K; Tembo T; Mutero P; Tauya T; Chitukuta M; Gati Mirembe B; Soto-Torres L; Brown ER; Baeten JM; van der Straten A;
AIDS Behav; 2021 Aug; 25(8):2430-2440. PubMed ID: 33713213
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
13. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence.
Stoner MCD; Brown ER; Palanee-Phillips T; Mansoor LE; Tembo T; Nair G; Akello C; Seyama L; Jeenarain N; Naidoo L; Mgodi N; Hunidzarira P; Chitukuta M; van der Straten A;
AIDS Behav; 2021 Dec; 25(12):4169-4179. PubMed ID: 33939034
[TBL] [Abstract][Full Text] [Related]
14. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
[TBL] [Abstract][Full Text] [Related]
15. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
[TBL] [Abstract][Full Text] [Related]
16. Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex.
Browne EN; Torjesen K; Mirembe BG; Palanee-Phillips T; Jeenarain N; Chitukuta M; Stoner MCD; Mansoor LE; Reddy K; Tauya TT; Naidoo L; Siva S; Richardson B; Dadabhai S; Seyama L; Soto-Torres L; van der Straten A;
AIDS Care; 2024 Jan; 36(1):80-86. PubMed ID: 37066990
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.
Balkus JE; Palanee-Phillips T; Reddy K; Siva S; Harkoo I; Nakabiito C; Kintu K; Nair G; Chappell C; Kiweewa FM; Kabwigu S; Naidoo L; Jeenarain N; Marzinke M; Soto-Torres L; Brown ER; Baeten JM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):e47-e51. PubMed ID: 28542081
[TBL] [Abstract][Full Text] [Related]
18. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.
Etima J; Katz AWK; Duby Z; Garcia M; Palanee-Phillips T; Reddy K; Mathebula F; Zimba C; Mansoor LE; Singh D; Manengamambo E; Naidoo S; Soto-Torres L; Montgomery ET;
AIDS Behav; 2022 May; 26(5):1597-1606. PubMed ID: 34727272
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.
Browne EN; Brown ER; Palanee-Phillips T; Reddy K; Naidoo L; Jeenarain N; Nair G; Husnik MJ; Singh D; Scheckter R; Soto-Torres L; Baeten JM; van der Straten A;
J Acquir Immune Defic Syndr; 2022 Aug; 90(4):418-424. PubMed ID: 35344520
[TBL] [Abstract][Full Text] [Related]
20. Patterns and predictors of high-risk sexual behavior in female partners of HIV-infected men with hemophilia.
Dublin S; Rosenberg PS; Goedert JJ
AIDS; 1992 May; 6(5):475-82. PubMed ID: 1616653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
